Background: Lung cancer is the main cause of cancer deaths worldwide. Around 1.8 million people are diagnosed worldwide with lung cancer each year. This accounts for about 13% of total cancer diagnoses making it the most common cancer disease. Lung cancer is also the type of cancer that has the highest mortality, killing approximately 1.6 million people annually.The highest incidence rates among men are in the United States and Eastern Europe, whereas the highest among women are in North America and Northern Europe. Aim of the Work: The aim of this study is to analyze the importance of clinicopathological parameters and treatment modality as prognostic factors affecting survival of patients diagnosed as Non-small cell lung cancer (NSCLC) and the quality of life. Methods: We retrospectively reviewed the clinical records of patients with inoperable stage III/IV NSCLC, who were treated at the department of Clinical Oncology, Ain Shams University Hospital and the International Medical center between 2009 and 2017. The association between the demographic and clinical characteristics and survival of these patients was analyzed. Results: A total of 69 patients (32 stage III& 39 stage IV) were identified and included in this study. Sex (males vs. females, p=0.04), Eastern cooperative Oncology group performance status (0 vs. 1 vs. 2, p=0.001), smoking habit (never vs. current vs. former, p=0.001), stage (IIIA vs. IIIB vs. IV, p=0.008) and the initial treatment (no vs. chemotherapy vs. concurrent chemoradiotherapy, p=0.001) were found to be factors affecting survival in univariate analyses. Sex and histological subtype did not affect survival. Performance status, stage and initial treatment were determined as the independent prognostic factors affecting survival in multivariate analyses. Conclusion: Performance status, stage and initial treatment with concurrent chemoradiotherapy in eligible patients were prognostic factors affecting overall survival of patients with advanced NSCLC.